Abstract
In 58 human gastric cancers, the expression of P‐glycoprotein (P‐gp) was evaluated immunohistochemically and chemosensitivity was determined using the in vitro succinate dehydrogenase inhibition (SDI) test. Tumors which contained over 75% stained cells were scored as positive, and 14 of 58 cases (24%) were positive. There was no significant correlation between P‐gp expression and clinicopathologic features. The succinate dehydrogenase (SD) activity for each drug of P‐gp positive and negative tumors was as follows: 81.8 ± 15.2% vs. 66.3 ± 16.1% for Adriamycin (ADM), 75.5 ± 14.2% vs. 59.1 ± 17.6% for aclacinomycin A (ACR), 71.7 ± 15.0% vs. 61.1 ± 14.0% for mitomycin C (MMC), and 57.5 ± 18.4% vs. 47.0 ± 16.7% for cisplatin (CDDP). The increase in SD activity was evident in P‐gp positive tumors compared with negative ones in cases of ADM (P = 0.0044), ACR (P = 0.0105), and MMC (P = 0.0353). We suggested that P‐gp expression is closely related to chemosensitivities of human gastric cancers to anthracyclines. © 1994 Wiley‐Liss, Inc.
| Original language | English |
|---|---|
| Pages (from-to) | 135-139 |
| Number of pages | 5 |
| Journal | Seminars in Surgical Oncology |
| Volume | 10 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Jan 1 1994 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Surgery
- Oncology
Cite this
Expression of P‐glycoprotein influences resistance against anthracyclines in clinical gastric carcinomas. / Orita, Hiroyuki; Maehara, Yoshihiko; Anai, Hideaki; Baba, Hideo; Kusumoto, Hiroki; Korenaga, Daisuke; Sugimachi, Keizo.
In: Seminars in Surgical Oncology, Vol. 10, No. 2, 01.01.1994, p. 135-139.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Expression of P‐glycoprotein influences resistance against anthracyclines in clinical gastric carcinomas
AU - Orita, Hiroyuki
AU - Maehara, Yoshihiko
AU - Anai, Hideaki
AU - Baba, Hideo
AU - Kusumoto, Hiroki
AU - Korenaga, Daisuke
AU - Sugimachi, Keizo
PY - 1994/1/1
Y1 - 1994/1/1
N2 - In 58 human gastric cancers, the expression of P‐glycoprotein (P‐gp) was evaluated immunohistochemically and chemosensitivity was determined using the in vitro succinate dehydrogenase inhibition (SDI) test. Tumors which contained over 75% stained cells were scored as positive, and 14 of 58 cases (24%) were positive. There was no significant correlation between P‐gp expression and clinicopathologic features. The succinate dehydrogenase (SD) activity for each drug of P‐gp positive and negative tumors was as follows: 81.8 ± 15.2% vs. 66.3 ± 16.1% for Adriamycin (ADM), 75.5 ± 14.2% vs. 59.1 ± 17.6% for aclacinomycin A (ACR), 71.7 ± 15.0% vs. 61.1 ± 14.0% for mitomycin C (MMC), and 57.5 ± 18.4% vs. 47.0 ± 16.7% for cisplatin (CDDP). The increase in SD activity was evident in P‐gp positive tumors compared with negative ones in cases of ADM (P = 0.0044), ACR (P = 0.0105), and MMC (P = 0.0353). We suggested that P‐gp expression is closely related to chemosensitivities of human gastric cancers to anthracyclines. © 1994 Wiley‐Liss, Inc.
AB - In 58 human gastric cancers, the expression of P‐glycoprotein (P‐gp) was evaluated immunohistochemically and chemosensitivity was determined using the in vitro succinate dehydrogenase inhibition (SDI) test. Tumors which contained over 75% stained cells were scored as positive, and 14 of 58 cases (24%) were positive. There was no significant correlation between P‐gp expression and clinicopathologic features. The succinate dehydrogenase (SD) activity for each drug of P‐gp positive and negative tumors was as follows: 81.8 ± 15.2% vs. 66.3 ± 16.1% for Adriamycin (ADM), 75.5 ± 14.2% vs. 59.1 ± 17.6% for aclacinomycin A (ACR), 71.7 ± 15.0% vs. 61.1 ± 14.0% for mitomycin C (MMC), and 57.5 ± 18.4% vs. 47.0 ± 16.7% for cisplatin (CDDP). The increase in SD activity was evident in P‐gp positive tumors compared with negative ones in cases of ADM (P = 0.0044), ACR (P = 0.0105), and MMC (P = 0.0353). We suggested that P‐gp expression is closely related to chemosensitivities of human gastric cancers to anthracyclines. © 1994 Wiley‐Liss, Inc.
UR - http://www.scopus.com/inward/record.url?scp=0028355797&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028355797&partnerID=8YFLogxK
U2 - 10.1002/ssu.2980100215
DO - 10.1002/ssu.2980100215
M3 - Article
C2 - 7914378
AN - SCOPUS:0028355797
VL - 10
SP - 135
EP - 139
JO - Journal of Surgical Oncology
JF - Journal of Surgical Oncology
SN - 0022-4790
IS - 2
ER -